



16C1

3122

FEB 24 2000

TECH CENTER 1600/2900

1632 WD

BOX 13/B  
B. Webb  
4-12-00

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson

ELI LILLY AND COMPANY

Date February 17, 2000

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thomas Frank Bumol, et al. )  
  )  
Serial No. : 09/280,567                      ) Attention:  
  ) Branch Manager  
Filed: March 30, 1999                        )  
For: THERAPEUTIC APPLICATIONS OF            )  
      mFLINT POLYPEPTIDES                    )  
Docket No. : X-12915                         )

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents

Washington, D. C. 20231

Attention: Box Sequence

Sir:

This is in response to a "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" dated February 8, 2000, noting the absence of an acceptable Sequence Listing.

Enclosed herewith are:

- 1) a copy of the Notice;
- 2) a computer-readable copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(e);
- 3) a paper copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(c);
- 4) an affirmation pursuant to 37 C.F.R. § 1.821(f); and

FEB 29 2000

TECH CENTER 1600/2900

Serial No. 09/280,567

- 5) a Preliminary Amendment amending the specification to include the sequence listing.

Respectfully submitted,



Thomas D. Webster  
Attorney for Applicants  
Registration No. 39,872  
Phone: 317-276-3334

Eli Lilly and Company  
Patent Division/TDW  
Lilly Corporate Center  
Indianapolis, Indiana 46285

February 16, 2000